as CEO of development-stage biotech Exelixis for 14 years. While we see this as an ..... operations, we think his performance at Exelixis demonstrates a strong understanding of ..... by Stelios Papadopoulos (chairman at Exelixis and Regulus) at Biogen's annual meeting
Shares of Exelixis ( EXEL +21.8% ) romp on massive turnover of over 33M shares in response to this morning's report of positive results in a Phase
Top 10 Gainers: GRH +22% . SCOK +20% . KNDI +17% . ULTR +16% . PHX +15% . RADA +13% . EXEL +13% . URS +12% . CBAK +12% . CREG +13% . Top 10 Losers: VISN -14% . FHCO -13% . HLIT -11% . INVT -9% . GIGA -9
Feuerstein, David Miller elaborates on his view that Roche ( OTCQX:RHHBY +1.3% ) has a strong incentive to acquire Exelixis ( EXEL +10.7% ) in order to capture the full margin of the combination therapy cobimetinib and currently-approved Zelboraf
Gainers: CREG +20% . PGNX +14% . EXEL +12% . KNDI +11% . URS +8% . APP +7% . DGLY +6% . ICPT +5% . Losers: GTAT -6% . Post your comment!
the lower cost and shorter follow-up period. Cobimetinib is being co-developed by Genentech and Exelixis (NASDAQ: EXEL ). Shares of EXEL are up 16% premarket on light volume. Post your comment!
Exelixis and partner Roche have announced positive top-line results for their Phase ..... 50 per share fair value estimate and no-moat, stable trend rating for Exelixis , as we continue to await the more important Phase III results for Cometriq
Not much news on this one lately, depsite a big drop following Morningstar's latest reaffirmation. Still a Monringstar 5-star, but lots of shorts and mixed thoughts across traders. Just bought in at 3 and a quarter, so we'll see. Speculative at best at this point.
By Life Sciences Report : Oncology is king in biotech. Patients must be put on one drug, and then another, followed by another, as the disease progresses and becomes resistant. Multiple drugs will always be necessary, meaning multiple opportunities for drug companies. In this interview with The ...
Exelixis reported first-quarter results that were generally consistent with our ..... this year and represent the major catalysts for the firm. In addition, Exelixis ’ partnered asset with Roche, MEK inhibitor GDC-0973 (in combination